Építés alatt – nem éles oldal
Belépés
Toborzás még nem indultFázis nélkül

Xuanbai Yiqi Decoction for Sepsis: A Randomized Controlled Trial

A legfontosabb adatok

Ki végzi
Shanghai Jiao Tong University School of Medicine
Hol
Kína1 helyszín, 1 országbanVálassz országot a helyszínekhez
Azonosító
Állapot
Toborzás még nem indult
Résztvevők
280 fő, tervezett
Kezdés
2026. nov. 1.
Várható befejezés
2028. júl. 31.
A vizsgálat típusa
Beavatkozással járó, 4 csoportAz egyik csoport placebót (hatóanyag nélküli szert) kap, összehasonlításként.
A vizsgált kezelések
  • Xuanbai Chengqi Decoction
  • Xuanbai Chengqi Decoction; Forest-Cultivated Ginseng
  • Xuanbai Yiqi Decoction
  • Inactive Chinese Herbal Decoction Placebo
A regiszteradat frissítve
2026. október 28.

Ki vehet részt

Életkor
18 év – 80 év
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 9 feltétel megnézéseKevesebb

Ki vehet részt

  • Age ≥18 years and ≤80 years
  • Patients meeting the updated diagnostic criteria for sepsis (Sepsis-3), defined as infection-induced organ dysfunction with an increase of ≥2 points from baseline in the Sequential Organ Failure Assessment (SOFA) score (see table)
  • Provision of signed informed consent. Patients must meet all of the above criteria to be eligible for inclusion

Ki nem vehet részt

  • Concurrent autoimmune disease
  • Concurrent psychiatric disorders
  • Patients with advanced-stage cancer
  • Chronic failure of the heart, lung, liver, or kidney before admission, defined as:; Chronic heart failure: long-term use of a left ventricular assist device (LVAD) or inotropic agents such as milrinone; ii. Chronic respiratory failure: long-term use of a home non-invasive oxygen therapy device; iii. Liver function classified as Child-Pugh class C; iv. Chronic renal failure: requiring regular hemodialysis
  • Known allergic diathesis or hypersensitivity to any study drug. Patients meeting any of the above criteria will be excluded
  • Pregnant or breastfeeding women

A fő feltételek kérdésként

Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.

  • 18 és 80 év között vagy?

Hol van ez a vizsgálat?

Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

Sepsis is life-threatening organ dysfunction caused by a dysregulated host response to infection. Multiple organ dysfunction syndrome (MODS) is the leading cause of sepsis-related death. Early in sepsis, intestinal barrier injury and gut microbiota dysbiosis occur, and gut-derived toxins and inflammatory cytokines act on the lungs and the whole body via the gut-liver-lung axis, representing an important pathophysiological mechanism. In the intermediate and late stages of the disease, patients generally develop immunosuppression. Our team intends to establish a Traditional Chinese Medicine (TCM)-based comprehensive intestinal management protocol. Xuanbai Chengqi Decoction will be used in early sepsis. In the intermediate-to-late stage, when immunosuppression occurs (monocytic HLA-DR [mHLA-DR] expression <30%, decreased CD3+ and CD4+ lymphocyte counts, and a reduced CD4+/CD8+ ratio), Xuanbai Yiqi Decoction supplemented with forest-cultivated ginseng will be used, combined with acupuncture, to protect multiple organs including the intestine and lungs and to modulate immunity.This is a prospective, randomized, double-blind, placebo-controlled clinical trial enrolling 280 patients with sepsis hospitalized in the Department of Emergency Medicine and the Department of Critical Care Medicine at Ruijin Hospital. Patients with sepsis who meet all inclusion and exclusion criteria at admission will be randomly assigned to the control group, Xuanbai Chengqi Decoction group, Xuanbai Chengqi Decoction plus forest-cultivated ginseng group, or Xuanbai Yiqi Decoction group. The granules will be dissolved in 100 mL of warm water and administered once daily via a nasogastric tube for 7 consecutive days, in addition to standard sepsis treatment.The primary outcome is improvement in the Sequential Organ Failure Assessment (SOFA) score at day 7 (a measure of organ function). Secondary outcomes include disseminated intravascular coagulation (DIC) score, coagulation tests, endothelial injury and platelet markers, inflammatory markers, 28-day mortality, intensive care unit (ICU) and hospital length of stay, and adverse events.The study is funded by Ruijin Hospital and is conducted as an investigator-initiated trial.

A vizsgálat 4 csoportja

  • Xuanbai Chengqi Decoction GroupA vizsgált kezelés

    In addition to standard Western medical treatment for sepsis, participants receive Xuanbai Chengqi Decoction on days 1-7 after enrollment. The decoction consists of raw gypsum 30 g, raw rhubarb 12 g, bitter apricot seed 18 g, and Trichosanthes peel 18 g; it is decocted in water to 100 mL and administered twice daily.

    Kezelés: Xuanbai Chengqi Decoction

  • Xuanbai Chengqi Decoction + Forest-Cultivated Ginseng GroupA vizsgált kezelés

    In addition to standard Western medical treatment for sepsis, participants receive Xuanbai Chengqi Decoction on days 1-7 after enrollment, with concurrent monitoring of immune function. If immunosuppression occurs (mHLA-DR \<30%, decreased CD3+ and CD4+ lymphocytes, and reduced CD4+/CD8+ ratio), forest-cultivated ginseng 9 g is added to Xuanbai Chengqi Decoction. The modified decoction consists of raw gypsum 30 g, raw rhubarb 12 g, bitter apricot seed 18 g, Trichosanthes peel 18 g, and forest-cultivated ginseng 9 g; it is decocted in water to 200 mL and administered once daily.

    Kezelés: Xuanbai Chengqi Decoction; Forest-Cultivated Ginseng

  • Xuanbai Yiqi Decoction GroupA vizsgált kezelés

    In addition to standard Western medical treatment for sepsis, participants receive Xuanbai Yiqi Decoction on days 1-7 after enrollment. The decoction consists of raw gypsum 30 g, raw rhubarb 12 g, bitter apricot seed 18 g, Trichosanthes peel 18 g, and forest-cultivated ginseng 3 g; it is decocted in water to 200 mL and administered once daily.

    Kezelés: Xuanbai Yiqi Decoction

  • Control GroupPlacebo, összehasonlításként

    In addition to standard Western medical treatment for sepsis, participants receive an inactive Chinese herbal decoction placebo on days 1-7 after enrollment. The placebo is designed to simulate odor and to ensure physicochemical properties comparable to the investigational drugs, with the same administration route and treatment duration.

    Kezelés: Inactive Chinese Herbal Decoction Placebo

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
Efficacy and Safety of Xuanbai Yiqi Decoction in Patients With Sepsis: a Randomized, Double-blind, Controlled, Four-arm, Prospective Trial
Kérdések a feltételekről
Forrás: NCT07902024: ki vehet részt
A regiszteradat frissítve
2026. október 28.